Latest Insider Transactions at Meridian Bioscience Inc (VIVO)
This section provides a real-time view of insider transactions for Meridian Bioscience Inc (VIVO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MERIDIAN BIOSCIENCE INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MERIDIAN BIOSCIENCE INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2022
|
David Phillips Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+34.81%
|
$135,000
$18.54 P/Share
|
|
Dec 15
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,985
-3.16%
|
$33,745
$17.92 P/Share
|
|
Dec 15
2021
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-0.38%
|
$5,440
$17.92 P/Share
|
|
Nov 15
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,807
-5.71%
|
$76,140
$20.16 P/Share
|
|
Nov 15
2021
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
4,269
-4.87%
|
$85,380
$20.16 P/Share
|
|
Nov 15
2021
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,232
-5.26%
|
$44,640
$20.16 P/Share
|
|
Nov 15
2021
|
John P. Kenny Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
155,511
+36.97%
|
-
|
|
Nov 15
2021
|
John P. Kenny Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
155,511
-58.65%
|
-
|
|
Nov 15
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
32,557
+32.79%
|
-
|
|
Nov 15
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Other acquisition or disposition
|
Direct |
32,557
-48.8%
|
-
|
|
Nov 15
2021
|
Tony Serafini Lamanna Executive VP-Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
24,343
+36.45%
|
-
|
|
Nov 15
2021
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Other acquisition or disposition
|
Direct |
24,343
-57.36%
|
-
|
|
Nov 15
2021
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Grant, award, or other acquisition
|
Direct |
32,709
+27.18%
|
-
|
|
Nov 15
2021
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Other acquisition or disposition
|
Direct |
32,709
-37.32%
|
-
|
|
Nov 04
2021
|
John P. Kenny Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,472
+17.56%
|
-
|
|
Nov 04
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,593
+13.7%
|
-
|
|
Nov 04
2021
|
Tony Serafini Lamanna Executive VP-Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
10,593
+19.98%
|
-
|
|
Nov 04
2021
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Grant, award, or other acquisition
|
Direct |
10,593
+10.78%
|
-
|
|
Mar 17
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-12.57%
|
$750,000
$25.0 P/Share
|
|
Mar 10
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.02%
|
$250,000
$25.0 P/Share
|
|
Feb 16
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,359
-0.94%
|
$70,770
$30.35 P/Share
|
|
Feb 16
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,082
+0.82%
|
$20,820
$10.1 P/Share
|
|
Feb 12
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,181
-9.52%
|
$785,430
$30.14 P/Share
|
|
Feb 12
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,097
+7.75%
|
$230,970
$10.1 P/Share
|
|
Feb 11
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,320
-0.52%
|
$39,600
$30.0 P/Share
|
|
Feb 11
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,164
+0.46%
|
$11,640
$10.1 P/Share
|
|
Feb 08
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
68,288
-21.31%
|
$1,980,352
$29.86 P/Share
|
|
Feb 08
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
66,134
+9.45%
|
$793,608
$12.3 P/Share
|
|
Feb 08
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Open market or private sale
|
Direct |
6,254
-10.03%
|
$187,620
$30.0 P/Share
|
|
Feb 08
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+5.67%
|
$71,250
$19.56 P/Share
|
|
Feb 08
2021
|
John Mc Cune Rice Jr. Director |
SELL
Open market or private sale
|
Direct |
16,480
-40.28%
|
$461,440
$28.16 P/Share
|
|
Feb 08
2021
|
John Mc Cune Rice Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,205
+29.63%
|
$326,460
$12.01 P/Share
|
|
Feb 05
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-7.04%
|
$1,000,000
$25.0 P/Share
|
|
Feb 05
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Open market or private sale
|
Direct |
14,250
-19.55%
|
$370,500
$26.61 P/Share
|
|
Feb 05
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+13.37%
|
$213,750
$19.56 P/Share
|
|
Jan 27
2021
|
James M. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+8.46%
|
-
|
|
Jan 27
2021
|
Anthony P Bihl Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+11.08%
|
-
|
|
Jan 27
2021
|
Dwight E Ellingwood Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+9.76%
|
-
|
|
Jan 27
2021
|
John Mc Ilwraith Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+7.63%
|
-
|
|
Jan 27
2021
|
David Phillips Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+17.38%
|
-
|
|
Jan 27
2021
|
John Mc Cune Rice Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+10.13%
|
-
|
|
Jan 27
2021
|
Catherine Sazdanoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+10.33%
|
-
|
|
Jan 27
2021
|
Felicia Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+17.54%
|
-
|
|
Nov 25
2020
|
Anthony P Bihl Iii Director |
BUY
Open market or private purchase
|
Direct |
5,000
+31.54%
|
$85,000
$17.65 P/Share
|
|
Nov 23
2020
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.2%
|
$2,983
$19.08 P/Share
|
|
Nov 17
2020
|
David Phillips Director |
BUY
Bona fide gift
|
Direct |
796
+1.52%
|
-
|
|
Nov 17
2020
|
David Phillips Director |
SELL
Bona fide gift
|
Direct |
796
-12.07%
|
-
|
|
Nov 16
2020
|
Bryan T Baldasare Exec VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,991
-3.13%
|
$33,847
$17.11 P/Share
|
|
Nov 16
2020
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
2,509
-3.15%
|
$42,653
$17.11 P/Share
|
|
Nov 05
2020
|
Bryan T Baldasare Exec VP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,823
+14.54%
|
-
|